ClearPoint Neuro, Inc. will release its financial results for the second quarter of 2026 on Monday, August 3, 2026, after the market close. The company, which provides navigation systems for the brain and spine, scheduled a conference call to discuss its performance for the quarter.

Conference Call Details

Investors and analysts can access the live broadcast of the Q2 2026 review on August 3 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time). The online broadcast is available on the company's investor relations website. Telephone participants can dial (877) 407-9034 domestically or (201) 493-6737 internationally.

Replay Availability

A replay of the conference call will be accessible shortly after the call concludes until September 2, 2026. To listen to the replay, callers can dial (877) 660-6853 in the U.S. or Canada, or (201) 612-7415 internationally, using conference ID 413671. An online archive will also be available on the ClearPoint Neuro investor website.

About ClearPoint Neuro

ClearPoint Neuro is a device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine. The company provides clinical products and pre-clinical development services for controlled drug and device delivery. Its flagship product, the ClearPoint Neuro Navigation System, holds FDA clearance and CE-mark certification. The company collaborates with pharmaceutical and biotech firms, academic centers, and contract research organizations globally for Central Nervous System therapeutic delivery.

B. Riley Securities analyst Anderson Schock has maintained a Buy rating on ClearPoint Neuro, citing an updated valuation. The firm has raised the price target for the company's stock to $30, an increase from the previous target of $20.

Rating and Target Details

The revised price target reflects a more optimistic outlook for ClearPoint Neuro's performance. The company's stock trades on the NASDAQ under the ticker symbol CLPT.